2016-P: High Dose DACRA Treatment Improves Glucose Homeostasis, without Additional Weight Loss

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2016-P
Author(s):  
NINA SONNE ◽  
ANNA T. LARSEN ◽  
KIM V. ANDREASSEN ◽  
MORTEN ASSER KARSDAL ◽  
KIM HENRIKSEN
Keyword(s):  
Weight Loss ◽  
Glucose Homeostasis ◽  
High Dose ◽  
Additional Weight

Effect of high-dose vitamin D supplementation in combination with weight loss diet on glucose homeostasis, insulin resistance, and matrix metalloproteinases in obese subjects with vitamin D deficiency: a double-blind, placebo-controlled, randomized clinical trial

2020 ◽  
Vol 45 (10) ◽  
pp. 1092-1098
Author(s):  
Soodabeh Aliashrafi ◽  
Mehrangiz Ebrahimi-Mameghani ◽  
Mohammad Asghari Jafarabadi ◽  
Lida Lotfi-Dizaji ◽  
Elnaz Vaghef-Mehrabany ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Vitamin D ◽  
Weight Loss ◽  
Matrix Metalloproteinases ◽  
Vitamin D Deficiency ◽  
Glucose Homeostasis ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Model Assessment ◽  
Obese Subjects

As there is limited and inconsistent evidence in potential role of vitamin D on insulin resistance and matrix metalloproteinases, this study aimed to examine the effect of vitamin D supplementation on glucose homeostasis, insulin resistance, and matrix metalloproteinases in obese subjects with vitamin D deficiency. A total of 44 participants with serum 25-hydroxyvitamin D (25(OH)D) level ≤ 50 nmol/L and body mass index (BMI) 30–40 kg/m2 were randomly allocated into receiving weight reduction diet with either 50 000 IU vitamin D3 pearl (n = 22) or placebo (n = 22) once weekly for 12 weeks. Primary outcomes were changes in fasting serum glucose (FSG), homeostasis model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), and matrix metalloproteinases (MMPs). Secondary outcomes were changes in weight, BMI, 25(OH)D, calcium, phosphorous and parathyroid hormone (PTH). Sun exposure and dietary intakes were also assessed. Serum levels of 25(OH)D3 increased significantly with a simultaneous decrease in serum concentration of PTH in the vitamin D group. Weight, BMI, FSG, and MMP-9 decreased significantly in both groups, and there were significant differences in changes in weight, serum 25(OH)D3, PTH, and MMP-9 levels between the groups. Within- and between-groups analysis revealed no significant differences in serum calcium, phosphorous, serum insulin, HOMA-IR, QUICKI, and MMP-2 after intervention. Our results indicated that improvement in vitamin D status resulted in greater reductions in weight and MMP-9 during weight loss. These preliminary results are sufficient to warrant a bigger study group.

FIT – Do Something Different

2011 ◽  
Vol 70 (1) ◽  
pp. 25-34 ◽  
Author(s):  
Ben (C) Fletcher ◽  
Jill Hanson ◽  
Nadine Page ◽  
Karen Pine
Keyword(s):  
Weight Loss ◽  
Longitudinal Studies ◽  
Behavioral Intervention ◽  
Behavioral Flexibility ◽  
Calorie Intake ◽  
Life Skill ◽  
Behavioral Repertoire ◽  
Additional Weight

Two 3-month longitudinal studies examined weight loss following a 1-month behavioral intervention (FIT-DSD) focusing on increasing participants’ behavioral flexibility and breaking daily habits. The goal was to break the distal habits hypothesized as playing a role in unhealthy dietary and activity behaviors. The FIT-DSD intervention required participants to do something different each day and to engage in novel weekly activities to expand their behavioral repertoire. These activities were not food- or exercise-related. In Study 1, the FIT-DSD program was compared with a control condition where participants engaged in daily tasks not expected to influence behavioral flexibility. Study 2 used an active or quasicontrol group in which half the participants were also on food diets. Measures in both studies were taken pre-, post-, and post-postintervention. In Study 1, FIT-DSD participants showed greater weight loss that continued post-postintervention. In Study 2, all participants on the FIT-DSD program lost weight, weight loss continued post-postintervention, and participants who were also dieting lost no additional weight. A dose relationship was observed between increases in behavioral flexibility scores and weight loss, and this relationship was mediated by calorie intake. Corresponding reductions in BMI were also present. Increasing behavioral flexibility may be an effective approach for tackling obesity and also provides affective and potential life-skill benefits.

Weight loss in obese men by caloric restriction and high-dose diazoxide–mediated insulin suppression

2008 ◽  
Vol 0 (0) ◽  
pp. 080512004419299-??? ◽  
Author(s):  
G. van Boekel ◽  
S. Loves ◽  
A. van Sorge ◽  
J. Ruinemans-Koerts ◽  
T. Rijnders ◽  
...  
Keyword(s):  
Weight Loss ◽  
Caloric Restriction ◽  
High Dose

Low-carbohydrate diets lead to greater weight loss and better glucose homeostasis than exercise: a randomized clinical trial

2021 ◽  
Vol 15 (3) ◽  
pp. 460-471
Author(s):  
Lingli Cai ◽  
Jun Yin ◽  
Xiaojing Ma ◽  
Yifei Mo ◽  
Cheng Li ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Randomized Clinical Trial ◽  
Glucose Homeostasis ◽  
Low Carbohydrate

scholarly journals Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved

Obesity Facts ◽  
2021 ◽  
pp. 1-7
Author(s):  
Liesbet Trenson ◽  
Sander Trenson ◽  
Falco van Nes ◽  
Carolien Moyson ◽  
Matthias Lannoo ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Weight Management ◽  
Real World ◽  
Subcutaneous Administration ◽  
Maximum Tolerated Dose ◽  
Significant Weight Loss ◽  
Additional Weight ◽  
Obstructive Sleep ◽  
Daily Dose

<b><i>Introduction:</i></b> Obesity is a global health challenge, and pharmacologic options are emerging. Once daily subcutaneous administration of 3 mg liraglutide, a glucagon like peptide-1 analogue, has been shown to induce weight loss in clinical trials, but real-world effectiveness data are scarce. <b><i>Methods:</i></b> It is a single-centre retrospective cohort study of patients who were prescribed liraglutide on top of lifestyle adaptations after multidisciplinary evaluation. In Belgium, liraglutide is only indicated for weight management if the BMI is &#x3e;30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> with comorbidities such as dysglycaemia, dyslipidaemia, hypertension, or obstructive sleep apnoea. No indication is covered by the compulsory health care insurance. Liraglutide was started at 0.6 mg/day and uptitrated weekly until 3 mg/day or the maximum tolerated dose. Treatment status and body weight were evaluated at the 4-month routine visit. <b><i>Results:</i></b> Between June 2016 and January 2020, liraglutide was prescribed to 115 patients (77% female), with a median age of 47 (IQR 37.7–54.0) years, a median body weight of 98.4 (IQR 90.0–112.2) kg, a BMI of 34.8 (IQR 32.2–37.4) kg/m<sup>2</sup>, and an HbA1c level of 5.6%. Five (4%) patients did not actually initiate treatment, 9 (8%) stopped treatment, and 8 (7%) were lost to follow-up. At the 4-month visit, the median body weight had decreased significantly by 9.2% to 90.8 (IQR 82.0–103.5) kg (<i>p</i> &#x3c; 0.001). Patients using 3.0 mg/day (<i>n</i> = 60) had lost 8.0 (IQR 5.8–10.4) kg. The weight loss was similar (<i>p</i> = 0.9622) in patients that used a lower daily dose because of intolerance: 7.4 (IQR 6.2–9.6) kg for 1.2 mg (<i>n</i> = 3), 7.8 (IQR 4.1–7.8) kg for 1.8 mg (<i>n</i> = 16), and 9.0 (IQR 4.8–10.7) kg for 2.4 mg/day (<i>n</i> = 14). Weight loss was minimal if liraglutide treatment was not started or stopped prematurely (median 3.0 [IQR 0.3–4.8] kg, <i>p</i> &#x3c; 0.001, vs. on treatment). Further analysis showed an additional weight reduction of 1.8 kg in the patients that had started metformin &#x3c;3 months before the start of liraglutide (<i>p</i> &#x3c; 0.001). The main reasons for liraglutide discontinuation were gastrointestinal complaints (<i>n</i> = 5/9) and drug cost (<i>n</i> = 2/9). <b><i>Conclusion:</i></b> In this selected group of patients, the majority complied with liraglutide treatment over the initial 4-month period and achieved a significant weight loss, irrespective of the maximally tolerated maintenance dose. Addition of metformin induced a small but significant additional weight loss.

scholarly journals Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight Loss Intervention Randomized to High Dose ω-3 Fatty Acids vs Placebo

2021 ◽  
pp. canprevres.0656.2020
Author(s):  
Carol J Fabian ◽  
Christie A Befort ◽  
Teresa A Phillips ◽  
Jennifer L Nydegger ◽  
Amy L Kreutzjans ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Weight Loss ◽  
High Dose ◽  
Weight Loss Intervention

Type II cryoglobulinemic vasculitis in the setting of MALT lymphoma

2021 ◽  
Vol 14 (1) ◽  
pp. e236267
Author(s):  
Griffin J Reed ◽  
Antonious Z Hazim ◽  
Catalina Sanchez-Alvarez ◽  
Kenneth J Warrington
Keyword(s):  
Weight Loss ◽  
Malt Lymphoma ◽  
Lymphoid Tissue ◽  
Kidney Biopsy ◽  
Kidney Injury ◽  
High Dose ◽  
Cryoglobulinemic Vasculitis ◽  
Type Ii ◽  
Elevated Type ◽  
Underlying Malignancy

The objectives of this article are to present a case of type II cryoglobulinemic vasculitis, explain why mucosa-associated lymphoid tissue (MALT) lymphoma is an unusual cause of type II cryoglobulins and to discuss the aetiology, epidemiology, pathophysiology and treatment of cryoglobulinemic vasculitis. A 67-year-old woman presented with 4 months of weight loss, intermittent epistaxis and a purpuric skin rash. Prior to presentation, she was found to have an elevated rheumatoid factor. Further investigation revealed an acute kidney injury and elevated type II cryoglobulins suspicious for cryoglobulinemic vasculitis, which was confirmed by kidney biopsy. Additional workup for the weight loss included biopsy of newly found splenomegaly. Pathology revealed MALT lymphoma, a rare cause of type II cryoglobulinemic vasculitis. Successful medical therapy required treating the underlying malignancy with rituximab and high-dose steroids. After initial resolution of symptoms with this regimen, the patient’s vasculitis worsened, which was thought to be secondary to undertreatment of the lymphoma. Bendamustine was added to further treat the lymphoma, after which the patient recovered and was able to discharge without recurrence of symptoms at 6 months.

Sign in / Sign up

Export Citation Format

Share Document